DIAGNOSTIC SERVICES
Cytogenetics / Karyotyping
Karyotyping, also called whole genome chromosomal analysis, can differentiate primary and secondary changes; can address why, how, when and where chromosome abnormalities arise. Thus provide insights into diagnosis, prognosis, and prediction of disease in many acute and chronic leukemias and lymphomas. Traditional G-banding for at least 20 metaphase analyses with specific cell culturing and analyzed by two independent ASCP-certified Cytogenetic Technologists ensures optimal results.
Turnaround time 3-5 days
Over 99% culture success
Cell-specific culture
- Myeloid Disorders
- B-Lymphoid Disorders
- T-Lymphoid Disorders
- Myeloma
FISH
Fluorescence in situ hybridization (FISH) is a molecular cytogenetic method, and works as an adjunct to karyotype analysis for the detection of cytogenetic abnormalities. FISH can help provide clarification of G-banded abnormalities or identify cryptic abnormalities not visible by karyotype analysis. The main advantages of FISH include: high sensitivity and specificity, rapid turnaround time, capacity to analyze large numbers of cells, and ability to obtain adequate data from samples with a low mitotic index or terminally differentiated cells. Also, dividing cells are not required for FISH analysis using both fresh tissue and paraffin-embedded tissue.
In general, two hundred interphase cells are analyzed per probe by two independent ASCP certified Cytogenetic Technologist (100 cells/reader).
FISH is most useful when the analysis is targeted toward specific translocation, rearrangement and gain or loss that are known to be associated with a particular disease. We offer the following Disease-focused FISH panels with the best-in-industry turnaround time (1-2 days)
Turnaround time 2 days
Same day results for STAT cases
Complete suite of hematopoietic FISH probes
Disease-focused panels for
Hematologic FISH PANELS
| Acute Lymphoblastic Leukemia (ALL) |
|
BCR (22q11.2)/ABL1 (9q34.1) |
|
KMT2A (MLL) (11q23) |
|
ETV6 (12p13.2) |
|
IGH (14q32.3) |
| Acute Myeloid Leukemia (AML) |
|
D5S23,D5S721 (5p15.2)/EGR1 (5q31) |
|
CEP 7 (7p11.1-q11.1)/D7S522 (7q31) |
|
RUNX1T1 (8q21.3)/RUNX1 (21q22) |
|
KMT2A (MLL) (11q23) |
|
PML (15q24)/RARA (17q21.1-q21.2) |
|
CBFB (16q22) |
|
TP53 (17p13.1)/CEP 17 (17p11.1-q11.1) |
| B-cell Chronic Lymphocytic Leukemia (B-CLL) |
|
CCND1 (11q13.3)/IGH (14q32.3) |
|
ATM (11q22.3) |
|
CEP 12 (12p11.1-q11) |
|
D13S319 (13q14.3)/LAMP1 (13q34) |
|
TP53 (17p13.1) |
| High Grade B-cell Lymphoma (HGL) |
|
BCL6 (3q27) |
|
MYC (8q24.2) |
|
IGH (14q32.3)/BCL2 (18q21.3) |
| Chronic Myeloid Leukemia (CML) |
|
BCR (22q11.2)/ABL1 (9q34.1) |
| Eosinophilia |
|
FIP1L1 (4q12)/CHIC2 (4q12)/PDGFR-α (4q12) |
|
PDGFR-β (5q32) |
|
FGFR1 (8p11.23-p11.22)/CEP 8 (8p11.1-q11.1) |
|
PCM1 (8p22)/JAK2 (9p24.1) |
| Myelodysplastic Syndromes (MDS) |
|
D5S23,D5S721 (5p15.2)/EGR1 (5q31) |
|
CEP 7 (7p11.1-q11.1)/D7S522 (7q31) |
|
CEP 8 (8p11.1-q11.1) |
|
ETV6 (12p13.2) |
|
TP53 (17p13.1)/CEP 17(17p11.1-q11.1) |
|
D20S108 (20q12) |
| T-Cell Lymphoma |
|
CEP 7 (7p11.1-q11.1)/D7S522 (7q31) |
|
MYC (8q24.2)/IGH (14q32.3)/CEP 8 (8p11.1-q11.1) |
|
TRA/D (14q11.2) |
| Multiple Myeloma |
| 1pTEL/p58(1p36)/1q25 |
| CEP 9 (p11-q11)/CEP 15 (p11.2)/ TP53 (17p13.1) |
| CCND1(11q13.3)/IGH (14q32.3) |
| D13S319 (13q14.3)/LAMP1 (13q34) |
| IGH (14q32.3) |
| Multiple Myeloma Reflex |
| FGFR3 (4p16.3)/IGH (14q32.3) |
| IGH (14q32.3)/MAF (16q23) |
| IGH (14q32.3)/MAFB (20q12) |
| Myeloproliferative Neoplasms (MPN) |
|
CEP 8 (8p11.1-q11.1) |
|
ETV6 (12p13.2) |
|
D13S319 (13q14.3)/LAMP1 (13q34) |
|
D20S108 (20q12) |
|
BCR (22q11.2)/ABL1 (9q34.1) |
| Marginal Zone Lymphoma (MZL) |
|
CEP 3 (3p11.1-q11.1) |
|
MYB (6q23.2-q23.3) |
|
CEP 7 (7p11.1-q11.1)/D7S522 (7q31) |
|
CCND1 (11q13.3)/IGH (14q32.3) |
|
BIRC3 (11q22.1)/MALT1 (18q21.3)
|